Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose rituximab versus standard-dose rituximab in rheumatoid arthritis
2015-002156-27Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Proportion of disease flares. Started Sep 2015; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-002156-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002156-27.